Antibody-drug conjugate or ADC are an important class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. Unlike chemotherapy, ADCs are intended to target and kill only the cancer cells and spare healthy cells. ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic (anticancer) payload or drug. Antibody-drug conjugates are examples of bioconjugates and immunoconjugates.
By combining the unique targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, antibody-drug conjugates allow sensitive discrimination between healthy and diseased tissue. This means that, in contrast to traditional chemotherapeutic agents, antibody-drug conjugates target and attack the cancer cell so that healthy cells are less severely affected. For a video on the principles of ADCs see Nature Biotechnology Animation Antibody-drug conjugates.
Antibody-drug Conjugate 3D Molecular Visualization
Purchase 3D print
If you’d like a desktop model of an Antibody-drug Conjugate, you can purchase one from our Shapeways.com store. Available in multiple sizes.